250 related articles for article (PubMed ID: 8255478)
1. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Roberts JW; Cora-Locatelli G; Bravi D; Amantea MA; Mouradian MM; Chase TN
Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
[TBL] [Abstract][Full Text] [Related]
2. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
Adler CH; Singer C; O'Brien C; Hauser RA; Lew MF; Marek KL; Dorflinger E; Pedder S; Deptula D; Yoo K
Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959
[TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
[TBL] [Abstract][Full Text] [Related]
4. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
[TBL] [Abstract][Full Text] [Related]
5. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
[TBL] [Abstract][Full Text] [Related]
6. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Muhlack S; Herrmann L; Salmen S; Müller T
J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
[TBL] [Abstract][Full Text] [Related]
7. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K
Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498
[TBL] [Abstract][Full Text] [Related]
8. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
[TBL] [Abstract][Full Text] [Related]
9. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
Jorga KM; Nicholl DJ
Br J Clin Pharmacol; 1999 Sep; 48(3):449-52. PubMed ID: 10510160
[TBL] [Abstract][Full Text] [Related]
10. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers.
Sêdek G; Jorga K; Schmitt M; Burns RS; Leese P
Clin Neuropharmacol; 1997 Dec; 20(6):531-41. PubMed ID: 9403227
[TBL] [Abstract][Full Text] [Related]
11. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
Guay DR
Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
[TBL] [Abstract][Full Text] [Related]
12. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
Nyholm D; Johansson A; Lennernäs H; Askmark H
Eur J Neurol; 2012 Jun; 19(6):820-6. PubMed ID: 22136163
[TBL] [Abstract][Full Text] [Related]
13. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
Rajput AH; Martin W; Saint-Hilaire MH; Dorflinger E; Pedder S
Neurology; 1998 May; 50(5 Suppl 5):S54-9. PubMed ID: 9591523
[TBL] [Abstract][Full Text] [Related]
14. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
16. COMT inhibition in the treatment of Parkinson's disease.
Ruottinen HM; Rinne UK
J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
[TBL] [Abstract][Full Text] [Related]
17. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.
Limousin P; Pollak P; Gervason-Tournier CL; Hommel M; Perret JE
Lancet; 1993 Jun; 341(8860):1605. PubMed ID: 8099689
[No Abstract] [Full Text] [Related]
18. Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.
Hanson MR; Gálvez-Jiménez N
Semin Neurol; 2001; 21(1):15-22. PubMed ID: 11346021
[TBL] [Abstract][Full Text] [Related]
19. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Davis TL; Roznoski M; Burns RS
Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
[TBL] [Abstract][Full Text] [Related]
20. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
